Amgen Inc. (NASDAQ:AMGN) is Aaron Wealth Advisors LLC’s 4th Largest Position

Aaron Wealth Advisors LLC decreased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 189,882 shares of the medical research company’s stock after selling 8,782 shares during the period. Amgen accounts for 5.7% of Aaron Wealth Advisors LLC’s investment portfolio, making the stock its 4th biggest position. Aaron Wealth Advisors LLC’s holdings in Amgen were worth $49,491,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Capital Performance Advisors LLP acquired a new position in Amgen in the third quarter valued at $25,000. Hershey Financial Advisers LLC acquired a new stake in shares of Amgen during the 2nd quarter worth approximately $30,000. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen during the 3rd quarter worth approximately $29,000. Matrix Trust Co acquired a new stake in Amgen in the 3rd quarter valued at approximately $36,000. Finally, Livelsberger Financial Advisory bought a new position in Amgen during the 3rd quarter valued at $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 1.0 %

NASDAQ:AMGN opened at $272.11 on Friday. The company has a 50-day moving average price of $273.95 and a 200-day moving average price of $307.22. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock has a market cap of $146.27 billion, a price-to-earnings ratio of 34.84, a P/E/G ratio of 2.68 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue was up 23.2% on a year-over-year basis. During the same period last year, the company posted $4.96 EPS. Equities analysts predict that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.50%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is 115.24%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AMGN. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Wolfe Research began coverage on shares of Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Citigroup dropped their price objective on shares of Amgen from $335.00 to $310.00 in a research report on Wednesday, November 27th. TD Cowen lifted their target price on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Sanford C. Bernstein initiated coverage on shares of Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price target for the company. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.